Ava Scatoni

No ORCID on file · 9 papers in corpus · active 2024-2026

Study types

  • article 7
  • other 2

Condition tags

  • endometriosis 9
  • dysmenorrhea 3
article 2026
·doi:10.1016/j.jpag.2026.01.136
article 2026
·doi:10.1016/j.jpag.2026.01.143
article 2026
·doi:10.1016/j.jpag.2026.01.034
other 2026
Journal of pediatric and adolescent gynecology ·doi:10.1016/j.jpag.2026.02.008

STUDY OBJECTIVE: To evaluate the efficacy and tolerability of the gonadotropin-releasing hormone antagonist elagolix for endometriosis-associated pain symptoms in adolescents and young adults (AYAs) METHODS: We performed a retrospective coh…

article 2025
Fertility and sterility ·doi:10.1016/j.fertnstert.2025.07.020
article 2025
·doi:10.1097/ogx.0000000000001408

(Abstracted from J Pediatr Adolesc Gynecol 2024;37(4):402–406 One of the leading causes of dysmenorrhea in adolescents is endometriosis, or the growth of endometrial tissue outside the uterus. Endometriosis significantly impacts quality of …

article 2024
·doi:10.1016/j.fertnstert.2024.07.582
other 2024
Women's health (London, England) ·doi:10.1177/17455057241265081

BACKGROUND: Danazol is a synthetic progestin with androgenic effects that is approved by the Food and Drug Administration for treatment of endometriosis, benign fibrocystic breast disease, and hereditary angioedema. In recent years, increas…

article 2024
Journal of pediatric and adolescent gynecology ·doi:10.1016/j.jpag.2024.02.003

STUDY OBJECTIVE: To evaluate the efficacy and tolerability of a progestin-only pill containing 4 mg drospirenone (DRSP) as a hormonal therapy for the management of endometriosis-associated symptoms in adolescents and young adults. DESIGN: …